DNAPrint genomics Plays Key Role in Investigation of 11-Year-Old Florida Murder Case The Miami Herald Reports How Best-Selling Crime Novelist Introduced Company's Forensics Technology to Investigators SARASOTA, Fla., June 30 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. (OTC:DNAP) (BULLETIN BOARD: DNAP) today confirmed that the Company's forensics technology is playing a key role in an effort to solve a baffling 11-year-old murder case, thanks to the efforts of best-selling crime novelist Patricia Cornwall. A front-page article in the Monday, June 27, edition of The Miami Herald relates how Cornwall introduced the Company's DNA forensics technology to Hollywood, Fla., police, who had hit a stone wall in trying to find a suspect in the murder of an 85-year-old Mildred Weiss, a former legal secretary who was brutally slain in the laundry room of her apartment building in March 1994. A decade later, author Cornwall alerted Hollywood police to new cutting- edge technology developed by DNAPrint genomics. Police investigators then sent DNA recovered from the crime scene to the Company's laboratory for testing in May 2005. DNAPrint's analysis determined that the killer was black, confirming what police believed to be the case based on a composite sketch drawn from the description of a man seen in the area by local residents before the murder. The article and a companion story about the Company's DNAWitness(TM) forensic technology also discuss the role that DNAPrint genomics has played in other high-profile murder cases. DNAPrint's forensics technology has been used in nearly 100 law enforcement investigations since its introduction. Both of the articles can be accessed on-line at the newspaper's website at http://www.miami.com/mld/miamiherald/news/local/states/florida/counties/browar d_county/11993639.htm and http://www.miami.com/mld/miamiherald/news/front/11993603.htm . About DNAPrint genomics, Inc. DNAPrint genomics, Inc. ( http://www.dnaprint.com/ ) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. Forward-Looking Statements All statements in this press release that are not historical are forward- looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Company Contact: Hector J. Gomez, M.D., Ph.D. Chairman and CMO 813-909-2029 -or- Ron Stabiner The Wall Street Group, Inc. 212-888-4848 DATASOURCE: DNAPrint genomics CONTACT: Hector J. Gomez, M.D., Ph.D., Chairman and CMO, DNAPrint genomics, +1-813-909-2029; or The Wall Street Group, Inc., +1-212-888-4848, for DNAPrint genomics Web site: http://www.dnaprint.com/ http://www.miami.com/mld/miamiherald/news/front/11993603.htm http://www.miami.com/mld/miamiherald/news/local/states/florida/counties/browar d_county/11993639.htm

Copyright